Stockholders Approve Massive Increase in Authorized Shares and New Equity Incentive Plan

summarizeSummary

Curis stockholders approved a massive increase in authorized common stock and a new equity incentive plan, paving the way for significant future dilution.

check_boxKey Events · Financing and Capital Events · CRIS

• Authorized Common Stock Increased

  Stockholders approved an amendment to the Certificate of Incorporation, increasing the number of authorized common shares from 68,343,750 to 283,757,150. This authorizes the company to issue up to an additional 215,413,400 shares.

• New Equity Incentive Plan Approved

  The 2026 Incentive Plan was approved, initially authorizing 6,407,374 shares for awards, plus up to 3,474,867 shares from a prior plan, and an annual evergreen increase of up to 5% of outstanding shares.

• Issuance for Existing Convertibles Authorized

  Stockholders approved the issuance of shares upon conversion of Series B Preferred Stock and exercise of Series A, B, and C Warrants, and Pre-Funded Warrants, clearing the way for future dilution from these instruments.

auto_awesomeAnalysis · CRIS · Life Sciences

Curis, Inc. stockholders have approved a substantial increase in the company's authorized common stock, raising the limit from 68,343,750 to 283,757,150 shares. This represents an increase of over 215 million shares, significantly expanding the company's capacity for future equity issuance. Concurrently, a new 2026 Incentive Plan was approved, authorizing an initial pool of nearly 10 million shares for awards, with an additional annual evergreen provision. These actions, coupled with the authorization to issue shares for existing convertible securities, signal a high likelihood of substantial future dilution for existing shareholders. For a micro-cap company, this level of potential share issuance is a critical event that could significantly impact existing shareholder value, suggesting a need for significant capital raises or conversions.